Table 5.
Antibiotic use in neonates (initial and overall) within 3 days of life
| Antibiotics | EOS |
Non-EOS (n = 797) |
||
|---|---|---|---|---|
|
Culture proven (n = 83) |
Culture negative (n = 112) |
Absence of culture facility (n = 47) |
||
| Initial antibiotics | ||||
| Ampicillin / Amoxicillin | 76 (91.6%) | 47 (42.0%) | 3 (6.4%) | 156 (19.6%) |
| Gentamicin | 17 (20.5%) | 55 (49.1%) | 10 (21.3%) | 457 (57.3%) |
| Amikacin | 78 (94.0%) | 73 (65.2%) | 2 (4.3%) | 229 (28.7%) |
| Third-generation cephalosporin | 27 (32.5%) | 26 (23.2%) | 41 (87.2%) | 181 (22.7%) |
| Overall antibiotics | ||||
| Ampicillin / Amoxicillin | 76 (91.6%) | 48 (42.9%) | 3 (6.4%) | 157 (19.7%) |
| Penicillin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
| Gentamicin | 19 (22.9%) | 55 (49.1%) | 10 (21.3%) | 458 (57.5%) |
| Netilmicin | 39 (47.0%) | 8 (7.1%) | 0 (0.0%) | 12 (1.5%) |
| Amikacin | 82 (98.8%) | 74 (66.1%) | 2 (4.3%) | 229 (28.7%) |
| Ampicillin-Sulbactam | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Amoxicillin-Clavulanic acid | 3 (3.6%) | 45 (40.2%) | 0 (0.0%) | 398 (49.9%) |
| Piperacillin-tazobactam | 3 (3.6%) | 28 (25%) | 0 (0.0%) | 93 (11.4%) |
| Imipenem | 4 (4.8%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) |
| Meropenem | 20 (24.1%) | 9 (8.0%) | 0 (0.0%) | 16 (2.0%) |
| Doripenem | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.4%) |
| Third-generation cephalosporin | 68 (81.9%) | 28 (25.0%) | 41 (87.2%) | 182 (22.8%) |
| Fourth-generation cephalosporin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (0.3%) |
| Ciprofloxacin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
| Vancomycin | 1 (1.2%) | 0 (0.0%) | 3 (6.4%) | 3 (0.4%) |
| Metronidazole | 11 (13.3%) | 5 (4.5%) | 0 (0.0%) | 15 (1.9%) |